Ozmosi | PF-04523655 Drug Profile

Product Description

For diabetic macular edema (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00701181)

Mechanisms of Action: RTP801 Inhibitor

Novel Mechanism: Yes

Modality: Nucleic Acid

Route of Administration: Injection

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Quark
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Choroidal Neovascularization|Macular Degeneration|Diabetes Complications|Macular Edema|Diabetic Retinopathy

Phase 1: Macular Degeneration|Choroidal Neovascularization

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT00725686	Wet AMD	P1	Completed	Choroidal Neovascularization\|Macular Degeneration	2010-11-01	2019-03-18	Treatments
NCT01445899	MATISSE	P2	Completed	Macular Edema\|Choroidal Neovascularization\|Diabetic Retinopathy	2013-11-01	2019-03-19
2011-004157-66	MATISSE STUDY	P2	Completed	Macular Edema	2013-09-13	2022-03-13	Treatments
2008-003210-10	2008-003210-10	P2	Completed	Macular Degeneration\|Choroidal Neovascularization	2011-07-07	2022-03-12	Treatments
NCT00701181	DEGAS	P2	Terminated	Diabetes Complications\|Diabetic Retinopathy\|Macular Edema	2011-01-01	2019-03-18	Treatments
2008-000349-68	2008-000349-68	P2	Terminated	Macular Edema	2010-12-17	2022-03-12	Treatments
NCT00713518	MONET	P2	Completed	Choroidal Neovascularization\|Macular Degeneration	2010-11-01	2019-03-18

Recent News Events

Date	Type	Title
06/10/2021	News Article	2021 Wet Age Related Macular Degeneration (Wet - AMD) Pipeline Insight Report - ResearchAndMarkets.com
04/01/2021	PubMed	RNA therapeutics in ophthalmology - translation to clinical trials.
02/01/2021	PubMed	Progress on ocular siRNA gene-silencing therapy and drug delivery systems.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

PF-04523655

Alternative Names: pf-04523655, pf04523655, pf 04523655 Clinical Status: Inactive Latest Update: 2021-06-10 Latest Update Note: News Article